|
rs10719
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Taken together, these findings suggested that DROSHA rs10719T>C polymorphism may be associated with bladder cancer risk in a Chinese population, and hsa-miR-27b can influence the expression of DROSHA protein by binding with 3'UTR.
|
24312312 |
2013 |
|
rs10743980
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with 2 variants of LRP6: rs10743980 were associated with a decreased risk of bladder cancer in the recessive model in the initial analysis (OR 0.76, 95% CI 0.58-0.99, p=0.039).
|
26173102 |
2015 |
|
rs10748835
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The combination of AS3MT haplotype 2 (AS3MT rs11191453, rs11191454, rs10748835, and rs1046778)'s high-risk haplotype (C-G-A-C, T-A-A-C, and T-G-G-T) was significantly associated with increased risk of BC.
|
29669044 |
2018 |
|
rs10748835
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs10759
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Reference SNP 10759 (rs10759) on the RGS4 gene demonstrated the greatest association with overall bladder cancer risk, conferring a 0.77-fold reduced risk with an increasing number of variant alleles (P < .001).
|
23529717 |
2013 |
|
rs10775480
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Our data suggest that SLC14A1 could be a unique urea transporter in the bladder that has the ability to influence urine concentration and that this mechanism might explain the increased bladder cancer susceptibility associated with rs10775480.
|
23754249 |
2013 |
|
rs10775480
|
|
|
0.710 |
GeneticVariation |
GWASDB |
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.
|
21824976 |
2011 |
|
rs10775480
|
|
T |
0.710 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies multiple loci associated with bladder cancer risk.
|
24163127 |
2014 |
|
rs10811474
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ASSET analyses identified four SNPs significantly associated with multiple cancers: rs3731239 (CDKN2A intronic) with ESCC, GC and BC (P = 3.96 × 10(-) (4)); rs10811474 (3' of IFNW1) with RCC and BrC (P = 0.001); rs12683422 (LINGO2 intronic) with RCC and BC (P = 5.93 × 10(-) (4)) and rs10511729 (3' of ELAVL2) with LC and BrC (P = 8.63 × 10(-) (4)).
|
25239644 |
2014 |
|
rs10936599
|
|
C |
0.720 |
GeneticVariation |
GWASDB |
Genome-wide association study identifies multiple loci associated with bladder cancer risk.
|
24163127 |
2014 |
|
rs10936599
|
|
|
0.720 |
GeneticVariation |
BEFREE |
At the end of the study, we suggested that there may exist an association between a combination of MYNN rs10936599 and TERC rs2293607 polymorphisms and development of bladder cancer in Turkish population.
|
30120764 |
2019 |
|
rs10936599
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Overall, seven of the 14 variants were significantly associated with bladder cancer risk (p = 9.763 × 10(-3) for rs9642880 at 8q24.21, p = 3.004 × 10(-3) for rs2294008 at 8q24.3, p = 0.012 for rs798766 at 4p16.3, p = 0.034 for rs1495741 at 8p22, p = 2.306 × 10(-4) for GSTM1, p = 8.507 × 10(-8) for rs17674580 at 18q12.3, p = 7.179 × 10(-4) for rs10936599 at 3q26.2) and the odds ratios (ORs) ranged from 1.13 to 1.65.
|
24740636 |
2014 |
|
rs11077654
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, rs11077654 was significantly associated with survival of bladder cancer patients (p = 0.046).
|
25900876 |
2015 |
|
rs1109324
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three additional SNPs in the promoter region (rs833052, rs1109324, and rs1547651) were associated with increased risk for bladder cancer: odds ratio (95% confidence interval): 2.52 (1.06-5.97), 2.74 (1.26-5.98), and 3.02 (1.36-6.63), respectively; and a polymorphism in intron 2 (rs3024994) was associated with reduced risk: 0.65 (0.46-0.91).
|
17319747 |
2007 |
|
rs11191438
|
|
|
0.010 |
GeneticVariation |
BEFREE |
AS3MT rs11191438 (C > G) G/G genotype, AS3MT rs10748835 (A > G) G/G genotype, and AS3MT rs1046778 (C > T) T/T genotype were found to be related to BC risk, where the odds ratio (OR) (95% CI) was 0.50 (0.31-0.82), 0.49 (0.30-0.79), and 0.54 (0.36-0.80), respectively.
|
29669044 |
2018 |
|
rs11191439
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191439
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191454
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs11249206
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Multifactor dimensionality reduction (MDR) analysis identified a significant more than multiplicative interaction between the SNP7 rs760805 AA and smoking and an additive interaction between the SNP3 rs11249206 TT and smoking on bladder cancer risk.
|
18684727 |
2008 |
|
rs1130214
|
|
|
0.010 |
GeneticVariation |
BEFREE |
None of the other examined polymorphisms (<i>AKT1</i> rs1130214, <i>AKT1</i> rs3730358, <i>mTOR</i> rs1883965) revealed significant association with BC.
|
29383014 |
2018 |
|
rs1130233
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, our findings suggest that <i>PIK3CA</i> rs6443624, <i>AKT1</i> rs2498801, <i>AKT1</i> rs1130233, as well <i>mTOR</i> rs2295080 polymorphism may be related to bladder cancer development in a sample of Iranian population.
|
29383014 |
2018 |
|
rs1130409
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This meta-analysis suggested that the APE1 T1349G (Asp148Glu) polymorphism was not associated with bladder cancer risk among Asians nor non-Asians.
|
23143180 |
2013 |
|
rs1130409
|
|
|
0.030 |
GeneticVariation |
BEFREE |
To explore the association between xerodema pigmentosum group D (XPD) Asp(312)Asn and Lys(751)Gln and apurinic apyrimidic endonuclease 1 (APE1) Asp(148)Glu gene polymorphism and risk of bladder cancer (BC) susceptibility.
|
19041121 |
2009 |
|
rs1130409
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Using multifactor dimensionality reduction approach, the four-factor model, including smoking status, OGG1 S326C (rs1052133), APEX1 D148E (rs3136820), and ADPRT762 (rs1136410), had the best ability to predict bladder cancer risk with the highest cross-validation consistency (100%) and the lowest prediction error (37.02%; P < 0.001).
|
17220334 |
2007 |
|
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
P53 Arg72Pro or codon 72 polymorphism has been indicated to increase the risk of developing certain cancers such as bladder cancer and cervical cancer.
|
26123760 |
2015 |